134 related articles for article (PubMed ID: 12686663)
21. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
Lepor NE; Gross SB; Daley WL; Samuels BA; Rizzo MJ; Luko SP; Hickey A; Buchbinder NA; Naqvi TZ
Am J Cardiol; 2000 Jul; 86(1):107-10. PubMed ID: 10867106
[No Abstract] [Full Text] [Related]
22. Appetite suppressants and valvular heart disease - a systematic review.
Loke YK; Derry S; Pritchard-Copley A
BMC Clin Pharmacol; 2002 Aug; 2():6. PubMed ID: 12194699
[TBL] [Abstract][Full Text] [Related]
23. [Valvular heart disease associated with benfluorex].
Rafel Ribera J; Casañas Muñoz R; Anguera Ferrando N; Batalla Sahún N; Castro Cels A; Pujadas Capmany R
Rev Esp Cardiol; 2003 Feb; 56(2):215-6. PubMed ID: 12605770
[TBL] [Abstract][Full Text] [Related]
24. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
Sachdev M; Miller WC; Ryan T; Jollis JG
Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
[TBL] [Abstract][Full Text] [Related]
25. [Appetite suppressants and heart valve disorders].
Adams C; Cohen A
Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670
[TBL] [Abstract][Full Text] [Related]
26. Chinese herb nephropathy is not a (dex)fenfluramine nephropathy but a serotonin nephropathy.
Malak J
J Altern Complement Med; 1998; 4(2):131-2. PubMed ID: 9628201
[No Abstract] [Full Text] [Related]
27. Food and Drug Administration criteria for the diagnosis of drug-induced valvular heart disease in patients previously exposed to benfluorex: a prospective multicentre study.
Maréchaux S; Rusinaru D; Jobic Y; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Garban T; Ennezat PV; Jeu A; Szymanski C; Tribouilloy C
Eur Heart J Cardiovasc Imaging; 2015 Feb; 16(2):158-65. PubMed ID: 25368209
[TBL] [Abstract][Full Text] [Related]
28. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
Delcroix M; Kurz X; Walckiers D; Demedts M; Naeije R
Eur Respir J; 1998 Aug; 12(2):271-6. PubMed ID: 9727773
[TBL] [Abstract][Full Text] [Related]
29. Operation for anorexigen-associated valvular heart disease.
Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
[TBL] [Abstract][Full Text] [Related]
30. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose.
Martinez MC; Nortier J; Vereerstraeten P; Vanherweghem JL
Nephrol Dial Transplant; 2002 Mar; 17(3):408-12. PubMed ID: 11865085
[TBL] [Abstract][Full Text] [Related]
31. Valve replacement for appetite suppressant-induced valvular heart disease.
Biswas SS; Donovan CL; Forbess JM; Royal SH; Landolfo KP
Ann Thorac Surg; 1999 Jun; 67(6):1819-22. PubMed ID: 10391313
[TBL] [Abstract][Full Text] [Related]
32. Operative finding of aortic cusp prolapse in benfluorex-induced aortic regurgitation.
Ennezat PV; Bruneval P; Maréchaux S; Bellemin JP; Senellart F; Arnaud-Crozat E; Ramadan R; Obadia JF; Touati G; Fleury JP; Tribouilloy C
Int J Cardiol; 2015; 186():231-2. PubMed ID: 25828122
[No Abstract] [Full Text] [Related]
33. Calcifications in benfluorex-induced valve heart disease: a misknown association.
Plurien F; Bruneval P; Jobic Y; Iung B; Ennezat PV
Cardiology; 2015; 130(2):87-90. PubMed ID: 25614032
[TBL] [Abstract][Full Text] [Related]
34. Dexfenfluramine and heart-valve regurgitation in Chinese patients with type 2 diabetes.
Ko GT; Chan HC; Chow CC
Hong Kong Med J; 2003 Aug; 9(4):243-6. PubMed ID: 12904610
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.
Schoonjans AS; Marchau F; Paelinck BP; Lagae L; Gammaitoni A; Pringsheim M; Keane MG; Ceulemans B
Curr Med Res Opin; 2017 Oct; 33(10):1773-1781. PubMed ID: 28704161
[TBL] [Abstract][Full Text] [Related]
36. Valvular heart disease associated with benfluorex therapy: high prevalence in patients with unexplained restrictive valvular heart disease.
Boudes A; Lavoute C; Avierinos JF; Le Dolley Y; Villacampa C; Salem A; Loundou AD; Michel N; Renard S; Habib G
Eur J Echocardiogr; 2011 Sep; 12(9):688-95. PubMed ID: 21810827
[TBL] [Abstract][Full Text] [Related]
37. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).
Nortier JL; Martinez MC; Schmeiser HH; Arlt VM; Bieler CA; Petein M; Depierreux MF; De Pauw L; Abramowicz D; Vereerstraeten P; Vanherweghem JL
N Engl J Med; 2000 Jun; 342(23):1686-92. PubMed ID: 10841870
[TBL] [Abstract][Full Text] [Related]
38. Increased risk of left heart valve regurgitation associated with benfluorex use in patients with diabetes mellitus: a multicenter study.
Tribouilloy C; Rusinaru D; Maréchaux S; Jeu A; Ederhy S; Donal E; Réant P; Arnalsteen E; Boulanger J; Ennezat PV; Garban T; Jobic Y
Circulation; 2012 Dec; 126(24):2852-8. PubMed ID: 23143159
[TBL] [Abstract][Full Text] [Related]
39. Restrictive organic mitral regurgitation associated with benfluorex therapy.
Tribouilloy C; Rusinaru D; Henon P; Tribouilloy L; Leleu F; Andréjak M; Sevestre H; Peltier M; Caus T
Eur J Echocardiogr; 2010 Aug; 11(7):614-21. PubMed ID: 20237052
[TBL] [Abstract][Full Text] [Related]
40. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial.
Weissman NJ; Panza JA; Tighe JF; Gwynne JT
Ann Intern Med; 2001 Feb; 134(4):267-73. PubMed ID: 11182836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
